EMA's March verdict on domperidone will consider Prescrire's "sudden death" claims
This article was originally published in Scrip
The European Medicines Agency, whose pharmacovigilance risk assessment committee (PRAC) is reviewing the safety of the anti-emetic drug domperidone, says the committee will consider claims by the French drug bulletin Prescrire that the product may have caused as many as 120 sudden deaths in France alone last year.
You may also be interested in...
New guidance from the UK covers the recognition of EU approvals, accelerated assessment, rolling reviews, and much else besides.
As negotiations between the UK and EU enter a crucial phase, the UK life sciences industry has called for more clarity and guidance on what companies can expect to face at the end of the Brexit transition period.
A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.